Oesophageal Cancer Clinical Trials
Oesophageal Cancer
Learn More About Oesophageal Cancer
For general information on oesophageal cancer (including risk factors, symptoms, diagnosis, and treatment) visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| HMBD-001-103 | Oesophageal Cancer (Squamous only) | A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers | Targeted | Humanized IgG1 anti-HER3 monoclonal antibody + Combo treatment for squamous HER3 Mutation. | Open - Recruiting | Hummingbird Bioscience | NCT05910827 | Enquire Now |
| ADCE-B05-001 | Oesophageal Cancer | A First-in-Human, Phase 1a/1b, Open-Label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of the Antibody Drug Conjugate ADCE-B05 in Patients with Advanced Solid Tumors | Immunotherapy | ADC anti-GPC1 IgG1 with a Topo-I inhibitor and P1021 | Open - Recruiting | Adcendo ApS | NCT07362888 | Enquire Now |
| ADCE-T02-01 | Oesophageal Cancer | First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting a tissue factor. | Open - Recruiting | Adcendo ApS | NCT06597721 | Enquire Now |